Pivotal readout
Bayer reports Chinese subgroup data for asundexian in stroke prevention
Adding asundexian to antiplatelet therapy cut recurrent ischemic stroke by 32% among Chinese patients in the phase 3 OCEANIC-STROKE trial, with no rise in major bleeding. The global study of more than 12,000 patients showed a 26% reduction. Bayer said the Chinese findings match the overall results and that the drug is approved in China.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.
